Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases
The increasing demand on diagnostic assays that are sensitive and specific for pathogenic antibodies, and the interest in identifying new antigens, prompted the development of cell-based assays for the detection of autoantibodies in myasthenia gravis and other autoimmune disorders. Cell-based assays...
Gespeichert in:
| Veröffentlicht in: | Experimental neurology 2015-08, Vol.270, p.66-71 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 71 |
|---|---|
| container_issue | |
| container_start_page | 66 |
| container_title | Experimental neurology |
| container_volume | 270 |
| creator | Rodriguez Cruz, P.M. Huda, S. López-Ruiz, P. Vincent, A. |
| description | The increasing demand on diagnostic assays that are sensitive and specific for pathogenic antibodies, and the interest in identifying new antigens, prompted the development of cell-based assays for the detection of autoantibodies in myasthenia gravis and other autoimmune disorders. Cell-based assays were initially used to show that clustering the AChR improved the positivity in myasthenia gravis, and similar assays have now been applied to detection of antibodies to neuromuscular junction candidate proteins such as LRP4 and agrin. In addition cell-based assays have been used in the routine detection of antibodies to proteins expressed on the surface of neurons (NMDAR, LGI1, CASPR2, AMPAR, GABA-A/B, GlyR, and DPPX) and glia (AQP4, MOG). Here, we summarize the findings in myasthenia and discuss the advantages, disadvantages and controversial issues of using cell-based assays in the detection of these antibodies, and their relevance to the testing of preclinical models of disease. |
| doi_str_mv | 10.1016/j.expneurol.2015.01.011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1688004642</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0014488615000758</els_id><sourcerecordid>1688004642</sourcerecordid><originalsourceid>FETCH-LOGICAL-c441t-40e26ce9ab3fc5de00ff0c026a4e4de5dffa0ae3c4a30b05860074a400c5663f3</originalsourceid><addsrcrecordid>eNqFkE9LAzEQxYMotla_gu7Ry9bJbjbdHkX8BwVB7DnMJhNNaXdrZiv225tS7VUYmGF4b4b3E-JKwliC1DeLMX2vW9rEbjkuQFZjkKnkkRhKmEJeqBKOxRBAqlzVtR6IM-YFAExVMTkVg6Ka1KXWMBSvc6as85ml5TJvkMllyIxbzkKbrbbI_Qe1AbP3iF-BM2xd1qVVTFMfms5t8xW5gH3yucCUDvC5OPG4ZLr47SMxf7h_u3vKZy-Pz3e3s9wqJftcARXa0hSb0tvKEYD3YKHQqEg5qpz3CEilVVhCA1WtASYKFYCttC59ORLX-7vr2H1uiHuzCrzLgS11GzZS1zWA0qpI0sleamPHHMmbdQwrjFsjweyAmoU5ADU7oAZkKpmcl79PNk1KevD9EUyC272AUtSvQNGwDdTaRCWS7Y3rwr9PfgDA-Ix_</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1688004642</pqid></control><display><type>article</type><title>Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Rodriguez Cruz, P.M. ; Huda, S. ; López-Ruiz, P. ; Vincent, A.</creator><creatorcontrib>Rodriguez Cruz, P.M. ; Huda, S. ; López-Ruiz, P. ; Vincent, A.</creatorcontrib><description>The increasing demand on diagnostic assays that are sensitive and specific for pathogenic antibodies, and the interest in identifying new antigens, prompted the development of cell-based assays for the detection of autoantibodies in myasthenia gravis and other autoimmune disorders. Cell-based assays were initially used to show that clustering the AChR improved the positivity in myasthenia gravis, and similar assays have now been applied to detection of antibodies to neuromuscular junction candidate proteins such as LRP4 and agrin. In addition cell-based assays have been used in the routine detection of antibodies to proteins expressed on the surface of neurons (NMDAR, LGI1, CASPR2, AMPAR, GABA-A/B, GlyR, and DPPX) and glia (AQP4, MOG). Here, we summarize the findings in myasthenia and discuss the advantages, disadvantages and controversial issues of using cell-based assays in the detection of these antibodies, and their relevance to the testing of preclinical models of disease.</description><identifier>ISSN: 0014-4886</identifier><identifier>EISSN: 1090-2430</identifier><identifier>DOI: 10.1016/j.expneurol.2015.01.011</identifier><identifier>PMID: 25783660</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Acetylcholine receptor ; Agrin ; Autoantibodies - analysis ; Autoimmune Diseases - diagnosis ; Autoimmune Diseases - immunology ; Biological Assay - methods ; Cell based assay ; ColQ ; Humans ; LRP4 ; MuSK ; Myasthenia Gravis - diagnosis ; Myasthenia Gravis - immunology ; Neuronal surface antibodies ; Seronegative MG ; Transfection</subject><ispartof>Experimental neurology, 2015-08, Vol.270, p.66-71</ispartof><rights>2015 Elsevier Inc.</rights><rights>Copyright © 2015 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c441t-40e26ce9ab3fc5de00ff0c026a4e4de5dffa0ae3c4a30b05860074a400c5663f3</citedby><cites>FETCH-LOGICAL-c441t-40e26ce9ab3fc5de00ff0c026a4e4de5dffa0ae3c4a30b05860074a400c5663f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.expneurol.2015.01.011$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/25783660$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rodriguez Cruz, P.M.</creatorcontrib><creatorcontrib>Huda, S.</creatorcontrib><creatorcontrib>López-Ruiz, P.</creatorcontrib><creatorcontrib>Vincent, A.</creatorcontrib><title>Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases</title><title>Experimental neurology</title><addtitle>Exp Neurol</addtitle><description>The increasing demand on diagnostic assays that are sensitive and specific for pathogenic antibodies, and the interest in identifying new antigens, prompted the development of cell-based assays for the detection of autoantibodies in myasthenia gravis and other autoimmune disorders. Cell-based assays were initially used to show that clustering the AChR improved the positivity in myasthenia gravis, and similar assays have now been applied to detection of antibodies to neuromuscular junction candidate proteins such as LRP4 and agrin. In addition cell-based assays have been used in the routine detection of antibodies to proteins expressed on the surface of neurons (NMDAR, LGI1, CASPR2, AMPAR, GABA-A/B, GlyR, and DPPX) and glia (AQP4, MOG). Here, we summarize the findings in myasthenia and discuss the advantages, disadvantages and controversial issues of using cell-based assays in the detection of these antibodies, and their relevance to the testing of preclinical models of disease.</description><subject>Acetylcholine receptor</subject><subject>Agrin</subject><subject>Autoantibodies - analysis</subject><subject>Autoimmune Diseases - diagnosis</subject><subject>Autoimmune Diseases - immunology</subject><subject>Biological Assay - methods</subject><subject>Cell based assay</subject><subject>ColQ</subject><subject>Humans</subject><subject>LRP4</subject><subject>MuSK</subject><subject>Myasthenia Gravis - diagnosis</subject><subject>Myasthenia Gravis - immunology</subject><subject>Neuronal surface antibodies</subject><subject>Seronegative MG</subject><subject>Transfection</subject><issn>0014-4886</issn><issn>1090-2430</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE9LAzEQxYMotla_gu7Ry9bJbjbdHkX8BwVB7DnMJhNNaXdrZiv225tS7VUYmGF4b4b3E-JKwliC1DeLMX2vW9rEbjkuQFZjkKnkkRhKmEJeqBKOxRBAqlzVtR6IM-YFAExVMTkVg6Ka1KXWMBSvc6as85ml5TJvkMllyIxbzkKbrbbI_Qe1AbP3iF-BM2xd1qVVTFMfms5t8xW5gH3yucCUDvC5OPG4ZLr47SMxf7h_u3vKZy-Pz3e3s9wqJftcARXa0hSb0tvKEYD3YKHQqEg5qpz3CEilVVhCA1WtASYKFYCttC59ORLX-7vr2H1uiHuzCrzLgS11GzZS1zWA0qpI0sleamPHHMmbdQwrjFsjweyAmoU5ADU7oAZkKpmcl79PNk1KevD9EUyC272AUtSvQNGwDdTaRCWS7Y3rwr9PfgDA-Ix_</recordid><startdate>20150801</startdate><enddate>20150801</enddate><creator>Rodriguez Cruz, P.M.</creator><creator>Huda, S.</creator><creator>López-Ruiz, P.</creator><creator>Vincent, A.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150801</creationdate><title>Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases</title><author>Rodriguez Cruz, P.M. ; Huda, S. ; López-Ruiz, P. ; Vincent, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c441t-40e26ce9ab3fc5de00ff0c026a4e4de5dffa0ae3c4a30b05860074a400c5663f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Acetylcholine receptor</topic><topic>Agrin</topic><topic>Autoantibodies - analysis</topic><topic>Autoimmune Diseases - diagnosis</topic><topic>Autoimmune Diseases - immunology</topic><topic>Biological Assay - methods</topic><topic>Cell based assay</topic><topic>ColQ</topic><topic>Humans</topic><topic>LRP4</topic><topic>MuSK</topic><topic>Myasthenia Gravis - diagnosis</topic><topic>Myasthenia Gravis - immunology</topic><topic>Neuronal surface antibodies</topic><topic>Seronegative MG</topic><topic>Transfection</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rodriguez Cruz, P.M.</creatorcontrib><creatorcontrib>Huda, S.</creatorcontrib><creatorcontrib>López-Ruiz, P.</creatorcontrib><creatorcontrib>Vincent, A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Experimental neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rodriguez Cruz, P.M.</au><au>Huda, S.</au><au>López-Ruiz, P.</au><au>Vincent, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases</atitle><jtitle>Experimental neurology</jtitle><addtitle>Exp Neurol</addtitle><date>2015-08-01</date><risdate>2015</risdate><volume>270</volume><spage>66</spage><epage>71</epage><pages>66-71</pages><issn>0014-4886</issn><eissn>1090-2430</eissn><abstract>The increasing demand on diagnostic assays that are sensitive and specific for pathogenic antibodies, and the interest in identifying new antigens, prompted the development of cell-based assays for the detection of autoantibodies in myasthenia gravis and other autoimmune disorders. Cell-based assays were initially used to show that clustering the AChR improved the positivity in myasthenia gravis, and similar assays have now been applied to detection of antibodies to neuromuscular junction candidate proteins such as LRP4 and agrin. In addition cell-based assays have been used in the routine detection of antibodies to proteins expressed on the surface of neurons (NMDAR, LGI1, CASPR2, AMPAR, GABA-A/B, GlyR, and DPPX) and glia (AQP4, MOG). Here, we summarize the findings in myasthenia and discuss the advantages, disadvantages and controversial issues of using cell-based assays in the detection of these antibodies, and their relevance to the testing of preclinical models of disease.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>25783660</pmid><doi>10.1016/j.expneurol.2015.01.011</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0014-4886 |
| ispartof | Experimental neurology, 2015-08, Vol.270, p.66-71 |
| issn | 0014-4886 1090-2430 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1688004642 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete |
| subjects | Acetylcholine receptor Agrin Autoantibodies - analysis Autoimmune Diseases - diagnosis Autoimmune Diseases - immunology Biological Assay - methods Cell based assay ColQ Humans LRP4 MuSK Myasthenia Gravis - diagnosis Myasthenia Gravis - immunology Neuronal surface antibodies Seronegative MG Transfection |
| title | Use of cell-based assays in myasthenia gravis and other antibody-mediated diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T08%3A11%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Use%20of%20cell-based%20assays%20in%20myasthenia%20gravis%20and%20other%20antibody-mediated%20diseases&rft.jtitle=Experimental%20neurology&rft.au=Rodriguez%20Cruz,%20P.M.&rft.date=2015-08-01&rft.volume=270&rft.spage=66&rft.epage=71&rft.pages=66-71&rft.issn=0014-4886&rft.eissn=1090-2430&rft_id=info:doi/10.1016/j.expneurol.2015.01.011&rft_dat=%3Cproquest_cross%3E1688004642%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1688004642&rft_id=info:pmid/25783660&rft_els_id=S0014488615000758&rfr_iscdi=true |